CLINICAL DIAGNOSTIC CRITERIA OF EFFICIENCY OF COMPLEX ETIOPATHOGENETIC THERAPY OF CHRONIC EPSTEIN-BARR VIRAL INFECTION
Objective. To evaluate the effectiveness of a complex etiopathogenetic therapy using the cosmetic Acegram of a chronic viral infection caused by the Epstein-Barr virus, with the determination in the saliva and blood of patients with this pathology of the virus genome by the method of polymerase chain reaction (PCR). Materials and methods. The observation was carried out on 34 patients who received complex therapy (the cycles of therapy were - valacyclovir (Valtrex) at a dose of 500 μg 2 times a day for 10 days, glucosaminylmuramyl dipeptide (Licopid) at a dose of 10 mg 2 times a day for 10 days - orally, the peptide of the active center of granulocyte-macrophage colony stimulating factor (Atsegram-spray) 3 times a day irrigation of mucous membranes for 10 days - local). If necessary, treatments were repeated 20 days after the end of therapy. All patients before treatment and 30, 60 days after therapy were examined for the presence of Epstein-Barr virus genomes in the saliva and blood using qualitative and quantitative PCR (DNA-technology test systems, Russia) using a DT-Lite device; at the same time in patients with serum, immunoglobulins of class G were determined for nuclear and capsid antigens of Epstein-Barr virus, using enzyme immunoassay (test systems manufactured by Vector Best, Russia). Results. The characteristic of the effect of complex therapy (combination of local and systemic treatment) on the clinical and laboratory efficacy of treatment of infection associated with Epstein-Barr virus is given. It was revealed that the use of a combination of these drugs after one or two courses of therapy led to the complete elimination of the Epstein-Barr virus from the main epitope of its persistence in 78.6% of chronic patients with this disease against the background of their clinical manifestations. Conclusion. The study showed that the most informative is the qualitative and quantitative determination of the Epstein-Barr virus genome by PCR, which, unlike the enzyme-linked immunosorbent assay (ELISA) to determine specific immunoglobulins, allows us to evaluate the effectiveness of etiopathogenetic therapy of this disease. The shown effectiveness of the developed scheme for the treatment of diseases caused by Epstein-Barr virus, allows us to recommend it for the treatment of chronic diseases of viral etiology.